In an increasingly competitive and data-driven business world, organizations must rely on accurate insights to guide their strategies and decisions. Understanding market behavior, tracking industry developments, and identifying growth opportunities are no longer optional—they are essential for survival and long-term success. Recognizing this growing demand for reliable intelligence, Emergen Research has launched its comprehensive Age-Related Macular Degeneration market research content, a powerful resource designed to support businesses across various industries.

One of the most notable aspects of this research is its strong focus on delivering actionable insights. Instead of simply presenting large volumes of raw data, the report is structured to help businesses translate information into practical strategies. Whether a company is planning expansion, optimizing operations, or exploring new opportunities, the recommendations provided in this content can play a crucial role in guiding decision-making processes.

The global age-related macular degeneration market size is expected to grow from 11.8 billion by the end of 2025 to 29.0 billion by 2035, registering a revenue CAGR of 10.5% during the forecast period. The major age-related macular degeneration market growth factors are the rising aging population and increasing prevalence of retinal disorders. As per the World Health Organization (WHO), the world's population aged 60 and older is projected to hit 2.1 billion by 2050.

This population trend is directly related to the increase in AMD cases, with almost 11 million individuals in the US already suffering, a figure projected to double by 2050. The growing pool of individuals under threat is prompting pharmaceutical and biotech companies to make more investment in developing successful age-related macular degeneration therapies.

Technology improvements in diagnostics and rising awareness levels for early diagnosis also propel the age-related macular degeneration market. In 2023, studies estimated late-stage AMD global prevalence at as much as 288 million through the year 2040 versus 196 million in 2020, indicative of the importance of having highly advanced treatment readily available.

Usage of new drug delivery systems, such as sustained-release implants, and studies on gene therapies are bringing new opportunities for growth. In addition to that, vision care programs initiated by the government and improvement in the healthcare infrastructure of developing nations are also contributing toward the growth of the market.

The Age-Related Macular Degeneration market research content has been developed through a rigorous process that combines advanced data analytics with deep industry expertise. Emergen Research’s team of analysts has carefully studied historical data, current trends, and future projections to create a comprehensive and reliable resource. The content includes a wide range of materials such as detailed market reports, whitepapers, case studies, and trend analyses. These resources cover multiple sectors including healthcare, technology, finance, manufacturing, and consumer goods, ensuring that the insights are relevant to businesses operating in diverse markets.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4923

Competitive landscape:-

The report also provides a comprehensive overview of the competitive landscape, which is critical for businesses aiming to maintain a strong market position. It highlights key players in the global Age-Related Macular Degeneration market and offers insights into their strategies, strengths, and recent developments. Information related to mergers and acquisitions, collaborations, technological advancements, and product launches is also included. This helps businesses understand how competitors are evolving and identify opportunities to differentiate themselves.

Increasing Geriatric Population and Technological Advancements Driving AMD Market Growth

The rising prevalence of age-related macular degeneration (AMD), fueled by a rapidly aging global population, is a primary growth driver for the AMD market. AMD is the primary cause of vision loss for individuals over 60 years of age, and the aging population is driving up demand for efficient treatment solutions. In the United States alone, close to 11 million individuals are living with some type of AMD, and this is expected to double in 2050. This direction is leading healthcare practitioners and drug manufacturers to focus on AMD-related research, which has led to the discovery of more precise therapies and a growth in the overall market size.

Meanwhile, the speed of advancements in diagnosis and treatment technology is driving market growth. Advanced diagnostic equipment such as optical coherence tomography (OCT) and fundus imaging are facilitating earlier diagnosis of AMD, which is essential for maintaining vision. At the treatment level, anti-VEGF treatments like Eylea and Lucentis have gained mainstream popularity, with Eylea alone having brought in over USD 9 billion in revenues worldwide in 2022.

New technologies like sustained-release drug delivery systems and gene therapies are also on the horizon, promising longer-lasting effects and fewer injection requirements. Such technological advancements are streamlining AMD treatment and making it more affordable, leading to the market's ongoing growth.

Another significant feature of the report is its detailed segmentation analysis. By dividing the Age-Related Macular Degeneration market into various categories such as product types, applications, end-user industries, and geographical regions, the report provides a deeper understanding of how different segments perform. This enables businesses to identify high-growth areas and focus their strategies accordingly. Understanding these segment-level dynamics can help organizations optimize resource allocation and improve overall efficiency.

Market competition in the age-related macular degeneration industry is characterized by the presence of global and regional players such as Alkeus Pharmaceuticals, Adverum Biotechnologies, Amgen, Bausch Health Companies, Astellas Pharma, Bayer AG. The AMD market is a rapidly changing and very competitive market fueled by the increasing incidence of the condition, especially in the growing elderly population around the world. The market has two broad segments: dry AMD and wet AMD, with wet AMD needing more aggressive treatment.

Strong emphasis is being placed on creating novel treatments, such as biologics, gene therapy, and newer technologies such as artificial intelligence for better diagnosis and treatment. Evolving despite the major improvements made in treatment options, the limitations include exorbitant treatment costs, needs for long-term management, and regulatory challenges.

In May 2025, Alkeus Pharmaceuticals announced positive Phase 2 results for ALK-001, a potential oral treatment for Stargardt disease (a form of inherited macular degeneration), with plans to advance to Phase 3. The market keeps changing with advances in personalized medicine and rising competition from both new and established companies as they aim to address the unmet needs of AMD patients.

Age-Related Macular Degeneration Market Leaders

• Alkeus Pharmaceuticals
• Adverum Biotechnologies
• Amgen
• Bausch Health Companies
• Astellas Pharma
• Bayer AG
• Coherus BioSciences
• Biogen
• STADA Arzneimittel AG
• F. Hoffmann-La Roche
• Novartis AG
• Kodiak Sciences
• Pfizer
• Sandoz Group AG
• Regeneron Pharmaceuticals

Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4923

Beyond competitive and segmentation analysis, the report is designed to cater to a wide range of stakeholders. Investors, venture capitalists, startups, and large enterprises can all benefit from the insights provided. Additionally, consulting firms, research organizations, and government bodies can use the information to support policy-making and strategic planning.

• Product Outlook (Revenue, USD Billion, 2021–2035)

  • Eylea and Eylea HD
  • Syfovre
  • Vabysmo
  • Lucentis
  • Others

• Molecule Outlook (Revenue, USD Billion, 2021–2035)

  • Aflibercept
  • Faricimab
  • Ranibizumab
  • Pegcetacoplan
  • Others

• Approval Type Outlook (Revenue, USD Billion, 2021–2035)

  • Biologial
  • Biosimilars

• Disease Type Outlook (Revenue, USD Billion, 2021–2035)

  • Wet AMD
  • Dry AMD

• End User Outlook (Revenue, USD Billion, 2021–2035)

  • Hospital
  • Long-Term Care Facilities
  • Specialty Centers

• Regional Outlook (Revenue, USD Billion, 2021–2035)

  • North America
    1. United States
    2. Canada
    3. Mexico
  • Europe
    1. Germany
    2. France
    3. United Kingdom
    4. Italy
    5. Spain
    6. Benelux
    7. Rest of Europe
  • Asia-Pacific
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Rest of Asia-Pacific
  • Latin America
    1. Brazil
    2. Rest of Latin America
  • Middle East and Africa
    1. Saudi Arabia
    2. UAE
    3. South Africa
    4. Turkey
    5. Rest of MEA

One of the key strengths of Emergen Research’s content is its commitment to providing up-to-date information. Markets are constantly changing due to technological advancements, economic shifts, and evolving consumer preferences. By regularly updating its research, Emergen Research ensures that businesses always have access to the latest insights. This allows organizations to remain agile and adapt quickly to new developments.

Another important advantage of this research is the inclusion of expert perspectives. The analysts behind the report bring years of experience and a deep understanding of industry trends. Their ability to interpret complex data and identify meaningful patterns adds significant value to the content. These insights not only help businesses understand current market conditions but also prepare for future challenges and opportunities.

Emergen Research also emphasizes clarity and usability in its content. The information is presented in a structured and easy-to-understand format, making it accessible even to those who may not have a strong background in market analysis. This user-friendly approach ensures that businesses of all sizes can benefit from the research.

Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/age-related-macular-degeneration-market

About Emergen Research
Emergen Research is a leading market research and consulting company that provides syndicated reports, customized research solutions, and expert consulting services. The company focuses on helping businesses understand market trends, analyze consumer behavior, and identify growth opportunities. With a strong commitment to accuracy and quality, Emergen Research continues to support organizations in making informed and strategic decisions.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com